Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutikizumab versus adalimumab in adults with active ulcerative colitis
NL-OMON60240Phase 2Withdrawn
- Sponsor
- AbbVie Inc.
- Start
- Aug 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of lutikizumab in autoimmune colitis, sponsored by AbbVie Inc. Primary endpoint: Percentage of participants who achieve endoscopic improvement. Planned start Aug 2024; status: withdrawn.
02
Drugs
lutikizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON60240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60240.